Eli Lilly (LLY) announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b trial

• TOGETHER-PsA open-label Phase 3b trial evaluated the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition
• At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and Zepbound compared to Taltz monotherapy.
• Adverse events in participants treated with concomitant administration of Taltz and Zepbound were generally mild to moderate, and the types of adverse events were consistent with the known safety profile of each medicine.

Eli Lilly's positive results from the TOGETHER-PsA trial suggest a robust advancement in treating psoriatic arthritis, particularly for patients with obesity. This could enhance the company's growth outlook and strengthen its competitive positioning in the pharmaceuticals sector as investors weigh the implications on future sales and market share across biotech competitors.